Acute hepatitis E infection during chemotherapy for lung cancer: a case report
Acute hepatitis E, one of the causes of acute liver injury, has been increasingly diagnosed in developed countries in recent years. Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. Thus, viral hepatitis, including hepatitis E, must be ruled out in the diagnosis of DILI. A 78-year-old woman with lung adenocarcinoma and multiple bone metastases received maintenance therapy with pemetrexed + pembrolizumab for a year. Increased aspartate aminotransferase and alanine aminotransferase levels, indicating acute liver injury, were obse...
Source: Chemotherapy - April 25, 2023 Category: Cancer & Oncology Source Type: research
New targeted drugs for acute myeloid leukemia and antifungals: pharmacokinetic challenges and opportunities
We describe potential strategies to minimize the consequences of DDI between triazole antifungals and targeted therapies for acute myeloid leukemia and the role that collaboration between clinical pharmacologists, hematologists and clini cal or laboratory microbiologists may have in these settings.
Key Messages
Therapeutic drug monitoring and clinical pharmacology stewardship could represent two strategies that best express multidisciplinary collaboration for improving patient management. (Source: Chemotherapy)
Source: Chemotherapy - March 31, 2023 Category: Cancer & Oncology Source Type: research
A 7-Day Decitabine-Included Conditioning Regimen Accelerated Donor Hematopoietic Engraftment while Reduced the Occurrence of Mucositis without Interfering with Prognosis
Conclusion: These results demonstrate that this 7-day decitabine-contained new conditioning regimen seems to be feasible and safe for patients with myeloid neoplasms who receive allo-HSCT, and a large-scale prospective study is needed to confirm the findings of this study. (Source: Chemotherapy)
Source: Chemotherapy - March 29, 2023 Category: Cancer & Oncology Source Type: research
A 7-day decitabine included conditioning regimen accelerated donor hematopoietic engraftment while reduced the occurrence of mucositis without interfering with prognosis
This study was to retrospectively evaluate a 7-day decitabine included regimen with reduced dose of idarubicin for patients with hematologic malignancies who underwent allo-HSCT.
Results: A total of 84 patients were enrolled, including 24 cases in 7-day and 60 cases in 5-day decitabine groups, respectively. Patients conditioned with 7-day decitabine regimen showed accelerated neutrophil (12.05 ±1.97 versus 13.86±3.15; u = 9.309, P (Source: Chemotherapy)
Source: Chemotherapy - March 29, 2023 Category: Cancer & Oncology Source Type: research
Circulating Endothelial Cell Kinetic in Patients with Multiple Myeloma Who Receive Autologous Hematopoietic Stem Cell Transplantation
Conclusion: CECs value may be a function of endothelial damage caused by conditioning regimen, as suggested by the increase of their level during the engraftment period. A more severe endothelial damage is reflected by the increase of infective complications in patients with higher CECs value at T3.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - March 9, 2023 Category: Cancer & Oncology Source Type: research
Circulating Endothelial Cell Kinetic in Patients with Multiple Myeloma Who Receive Autologous Hematopoietic Stem Cell Transplantation
Conclusion: CECs value may be a function of endothelial damage caused by conditioning regimen, as suggested by the increase of their level during the engraftment period. A more severe endothelial damage is reflected by the increase of infective complications in patients with higher CECs value at T3. (Source: Chemotherapy)
Source: Chemotherapy - March 9, 2023 Category: Cancer & Oncology Source Type: research
Circulating endothelial cell (CEC) kinetic in patients with Multiple Myeloma (MM) who receive Au-HSCT (Autologous Hematopoietic Stem Cell Transplantation)
Conclusion: CECs value may be a function of endothelial damage caused by conditioning regimen, as suggested by the increase of their level during the engraftment period. A more severe endothelial damage is reflected by the increase of infective complications in patients with higher CECs value at T3. (Source: Chemotherapy)
Source: Chemotherapy - March 9, 2023 Category: Cancer & Oncology Source Type: research
Erratum
Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2023 Category: Cancer & Oncology Source Type: research
Arrhythmia in Bruton Tyrosine Kinase Inhibitor-Treated Patients: Unanswered Questions
(No abstract allowed for commentary)Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2023 Category: Cancer & Oncology Source Type: research
Arrhythmia in Bruton Tyrosine Kinase Inhibitor-Treated Patients: Unanswered Questions
(No abstract allowed for commentary) (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2023 Category: Cancer & Oncology Source Type: research
Arrhythmia in Bruton Tyrosine Kinase Inhibitor treated patients: Unanswered Questions
(No abstract allowed for commentary) (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2023 Category: Cancer & Oncology Source Type: research
